1. Prognostic value of low microRNA-34a expression in human gastrointestinal cancer: a systematic review and meta-analysis
- Author
-
Xiao-Lin Liu, Ling Li, and Yan-Ling Chen
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,lcsh:RC254-282 ,03 medical and health sciences ,Gastrointestinal cancer ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,microRNA-34a ,Genetics ,medicine ,Biomarkers, Tumor ,Humans ,Stage (cooking) ,Gastrointestinal Neoplasms ,business.industry ,Hazard ratio ,Odds ratio ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Confidence interval ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,Meta-analysis ,030104 developmental biology ,MicroRNA 34a ,030220 oncology & carcinogenesis ,business ,Research Article - Abstract
Background Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs). Methods All eligible studies were found by searching PubMed, Web of Science and EMBASE, and survival results were extracted. Then, the hazard ratio (HR) with the corresponding 95% confidence interval (CI) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratios (ORs) and 95% CIs. Results A total of 20 studies were included in this meta-analysis. For overall survival (OS), lower miR-34a expression could probably predict poorer outcome in GICs, with a pooled HR of 1.86 (95% CI: 1.52–2.28, P P Conclusion This meta-analysis revealed that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS in GIC patients. In addition, the miR-34a expression level is relatively lower in patients with lymph node metastasis than in patients without lymph node metastasis, and decreased miR-34a expression levels are linked to poor tumour differentiation and late TNM stage. MiR-34a may become a new factor for the prognosis prediction and progression of GICs.
- Published
- 2021